Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Thrombocytopenia, Thrombosis
Interventions
Argatroban
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
Up to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Conditions
Heparin-induced Thrombocytopenia
Interventions
VLX-1005, Argatroban
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Suspected Heparin-Induced Thrombocytopenia
Interventions
Desirudin or Argatroban®
Drug
Lead sponsor
Canyon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 20 more
Conditions
Stroke, Cerebral Ischemia
Interventions
Argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Failure, Chronic, Renal Disease, End-Stage
Interventions
Argatroban
Drug
Lead sponsor
Texas Biotechnology Corporation
Industry
Eligibility
21 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
2
States / cities
Chicago, Illinois • Minneapolis, Minnesota
Conditions
Heparin-induced Thrombocytopenia
Interventions
Danaparoid Sodium, Argatroban
Drug
Lead sponsor
Aspen Global Incorporated
Industry
Eligibility
2 Weeks to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Durham, North Carolina + 2 more
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Conditions
Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody
Interventions
Argatroban and warfarin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ischemic Stroke
Interventions
Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase)
Drug
Lead sponsor
Andrew D. Barreto, MD
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Multi-arm Optimization of Stroke Thrombolysis

NCT03735979
Conditions
Acute Ischemic Stroke
Interventions
Argatroban, Eptifibatide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more
Completed Phase 1Phase 2 Interventional Results available

Argatroban Stroke Treatment - A Pilot Safety Study

NCT00268762
Conditions
Ischemic Stroke
Interventions
argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 2 more